Overview

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Status:
Active, not recruiting

Trial end date:
2024-05-10

Target enrollment:

Participant gender:

Summary

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab